



## COMPANY OVERVIEW

Cerecor is a clinical-stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and psychiatric disorders. Cerecor's lead drug candidate is CERC-301, which Cerecor currently intends to explore as a novel treatment for orphan neurological indications.

## RECENT NEWS

### Cerecor Reports Third Quarter 2018 Results

Nov 13 2018, 7:00 AM EST

### Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation

Oct 31 2018, 4:00 PM EDT

## STOCK OVERVIEW

Symbol	CERC
Exchange	Nasdaq
Market Cap	137.11m
Last Price	\$3.36
52-Week Range	\$1.55 - \$5.739

12/11/2018 04:00 PM EST

## INVESTOR RELATIONS

[ir@cerecor.com](mailto:ir@cerecor.com)

## MANAGEMENT TEAM

### Peter Greenleaf

Chief Executive Officer

### Joe Miller, CPA

Chief Financial Officer

### Matthew V. Phillips

Chief Commercial Officer

### Perry Calias, Ph.D.

Chief Scientific Officer

### Heather Fraser, Ph.D.

Vice President, Clinical Operations & Project Management

### Robert E. Swedberg, CPA

Vice President, Finance and Corporate Controller

### James A. Harrell, Jr.

Executive Vice President, Marketing and External Communications

## CERECOR, INC.

400 East Pratt Street  
Suite 606  
Baltimore, MD 21202

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.